このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Cencora 将来の成長

Future 基準チェック /36

Cencora利益と収益がそれぞれ年間10.1%と6.5%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に74.1% 12.6%なると予測されています。

主要情報

11.3%

収益成長率

14.0%

EPS成長率

Healthcare 収益成長	20.6%
収益成長率	6.9%
将来の株主資本利益率	96.9%
アナリストカバレッジ	Good
最終更新日	18 Sep 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

BST:ABG - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
9/30/2026	333,101	2,530	3,272	3,946	14
9/30/2025	313,022	2,274	2,847	3,408	15
9/30/2024	292,561	2,030	2,645	3,063	14
6/30/2024	283,831	1,856	3,831	4,311	N/A
3/31/2024	276,537	1,852	2,112	2,578	N/A
12/31/2023	271,579	1,867	3,630	4,086	N/A
9/30/2023	262,173	1,745	3,453	3,911	N/A
6/30/2023	254,425	1,689	2,793	3,249	N/A
3/31/2023	247,543	1,617	2,447	2,913	N/A
12/31/2022	241,805	1,729	2,057	2,550	N/A
9/30/2022	238,587	1,699	2,207	2,703	N/A
6/30/2022	236,325	1,842	2,061	2,548	N/A
3/31/2022	229,666	1,727	2,851	3,347	N/A
12/31/2021	221,101	1,614	2,174	2,627	N/A
9/30/2021	213,989	1,540	2,228	2,667	N/A
6/30/2021	204,321	-3,744	2,564	2,956	N/A
3/31/2021	196,282	-3,747	1,284	1,660	N/A
12/31/2020	194,546	-3,222	2,600	2,967	N/A
9/30/2020	189,894	-3,409	1,837	2,207	N/A
6/30/2020	186,287	1,570	1,250	1,581	N/A
3/31/2020	186,159	1,582	1,943	2,236	N/A
12/31/2019	182,061	649	1,710	2,008	N/A
9/30/2019	179,589	855	2,034	2,344	N/A
6/30/2019	177,248	956	2,018	2,337	N/A
3/31/2019	175,151	930	2,263	2,592	N/A
12/31/2018	172,866	1,190	1,538	1,880	N/A
9/30/2018	167,940	1,658	1,075	1,411	N/A
6/30/2018	163,763	1,081	1,783	2,126	N/A
3/31/2018	159,327	855	N/A	1,059	N/A
12/31/2017	155,441	979	N/A	1,945	N/A
9/30/2017	153,144	364	N/A	1,504	N/A
6/30/2017	151,584	855	N/A	1,478	N/A
3/31/2017	149,759	1,154	N/A	1,915	N/A
12/31/2016	148,310	1,346	N/A	1,997	N/A
9/30/2016	146,850	1,428	N/A	3,178	N/A
6/30/2016	144,759	1,643	N/A	2,986	N/A
3/31/2016	142,111	1,508	N/A	3,916	N/A
12/31/2015	139,082	391	N/A	3,777	N/A
9/30/2015	135,962	-138	N/A	3,922	N/A
6/30/2015	132,080	-431	N/A	3,591	N/A
3/31/2015	128,195	-658	N/A	2,989	N/A
12/31/2014	123,981	35	N/A	3,364	N/A
9/30/2014	119,569	282	N/A	1,465	N/A
6/30/2014	112,449	267	N/A	602	N/A
3/31/2014	104,008	344	N/A	157	N/A
12/31/2013	96,076	368	N/A	26	N/A
9/30/2013	87,959	493	N/A	788	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ABGの予測収益成長率 (年間10.1% ) は貯蓄率 ( 0.7% ) を上回っています。

収益対市場: ABGの収益 ( 10.1% ) German市場 ( 18.7% ) よりも低い成長が予測されています。

高成長収益: ABGの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: ABGの収益 ( 6.5% ) German市場 ( 5.2% ) よりも速いペースで成長すると予測されています。

高い収益成長: ABGの収益 ( 6.5% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ABGの自己資本利益率は、3年後には非常に高くなると予測されています ( 74.1 %)。

Cencora 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

Cencora, Inc. Reaffirms Guidance for Year 2024

Recent updates

Cencora, Inc. Elects Frank Clyburn as New Independent Director, Effective October 1, 2024

Third quarter dividend of US$0.51 announced

Third quarter 2024 earnings released: EPS: US$2.44 (vs US$2.37 in 3Q 2023)

Cencora, Inc. Declares Quarterly Cash Dividend, Payable on August 26, 2024

Cencora, Inc. to Report Q3, 2024 Results on Jul 31, 2024

Second quarter dividend of US$0.51 announced

Cencora, Inc. Declares Quarterly Cash Dividend on Common Share, Payable on May 24, 2024

Second quarter 2024 earnings released: EPS: US$2.11 (vs US$2.15 in 2Q 2023)

Cencora, Inc. (NYSE:COR) announces an Equity Buyback for $2,000 million worth of its shares.

Cencora, Inc. to Report Q2, 2024 Results on May 01, 2024

Cencora, Inc. Reaffirms Guidance for Year 2024

Cencora, Inc. Announces CEO Changes, Effective October 1, 2024

Cencora’s FormularyDecisions Launches Payer Resource for Cell and Gene Therapy Products

First quarter dividend of US$0.51 announced

First quarter 2024 earnings released: EPS: US$3.01 (vs US$2.35 in 1Q 2023)

Cencora, Inc. Declares Quarterly Cash Dividend on Common Share, Payable on February 26, 2024

Cencora, Inc., Annual General Meeting, Mar 12, 2024

Cencora, Inc., Annual General Meeting, Mar 12, 2024

Cencora, Inc. to Report Q1, 2024 Results on Jan 31, 2024

Now 20% undervalued

Chairman recently sold €8.1m worth of stock

Insider recently sold €1.8m worth of stock

Cencora, Inc. Declares Quarterly Dividend, Payable November 27, 2023

Full year 2023 earnings released: EPS: US$8.62 (vs US$8.15 in FY 2022)

Cencora, Inc. to Report Q4, 2023 Results on Nov 02, 2023

Amerisourcebergen Corporation Elects Werner Baumann and Lauren Tyler to Its Board of Directors

Third quarter 2023 earnings released: EPS: US$2.37 (vs US$1.95 in 3Q 2022)

AmerisourceBergen Corporation Declares Quarterly Cash Dividend, Payable on August 28, 2023

AmerisourceBergen Corporation to Report Q3, 2023 Results on Aug 02, 2023

TPG Inc. (NasdaqGS:TPG), AmerisourceBergen Corporation (NYSE:ABC) and the management team of OneOncology, Inc. acquired OneOncology, LLC from General Atlantic Service Company, L.P. and others.

Executive VP & Chief Legal Officer recently sold €675k worth of stock

Second quarter 2023 earnings released: EPS: US$2.15 (vs US$2.62 in 2Q 2022)

Insider recently sold €282k worth of stock

Senior VP recently sold €832k worth of stock

First quarter 2023 earnings released: EPS: US$2.35 (vs US$2.15 in 1Q 2022)

An unknown buyer acquired Brazil specialty business from AmerisourceBergen Corporation (NYSE:ABC).

AmerisourceBergen Corporation, Annual General Meeting, Mar 09, 2023

AmerisourceBergen Corporation, Annual General Meeting, Mar 09, 2023

AmerisourceBergen Corporation to Report Q1, 2023 Results on Feb 01, 2023

Insider recently sold €129k worth of stock

Executive VP & Chief Strategy Officer recently sold €475k worth of stock

Full year 2022 earnings released: EPS: US$8.15 (vs US$7.48 in FY 2021)

AmerisourceBergen Corporation Elects Redonda Miller to Its Board of Directors, Effective January 1, 2023

AmerisourceBergen Corporation has completed a Follow-on Equity Offering in the amount of $1.546 billion.

Full year 2022 earnings released: EPS: US$8.15 (vs US$7.48 in FY 2021)

AmerisourceBergen Corporation Appoints Robert P. Mauch as Executive Vice President and Chief Operating Officer

AmerisourceBergen Corporation to Report Q4, 2022 Results on Nov 03, 2022

AmerisourceBergen Elects Lorence H. Kim, M.D., to Its Board of Directors

AmerisourceBergen Corporation (NYSE:ABC) agreed to acquire Pharmalex Holding Gmbh from AUCTUS Capital Partners AG for €1.3 billion.

AmerisourceBergen Corporation (NYSE:ABC) agreed to acquire Pharmalex Holding Gmbh for €1.28 billion.

Insufficient new directors

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘